arXiv link Shanmuganathan, D., & Sivakumaran, N
Neem contact op met ons patintenondersteuningsteam om te bespreken welke andere afhaal- en bezorgopties voor u geschikt kunnen zijn
E., Lauzon, D
Strong appetite control without severe side effects
Protocol 1: Conservative sub-therapeutic approach Goal: Target inflammation with minimal metabolic impact Starting dose: 0.5 to 1.0 mg tirzepatide weekly Escalation: Increase by 0.25 to 0.5 mg every 4 to 6 weeks based on inflammatory marker response Target maintenance: The lowest dose that produces measurable CRP/IL-6 reduction Monitoring schedule: Baseline: hsCRP, IL-6, complete metabolic panel, body weight Week 4: hsCRP, symptom assessment Week 8: hsCRP, IL-6, body weight Every 8 weeks thereafter: full inflammatory panel Duration: Minimum 12 weeks to assess response, with ongoing reassessment Best for: Normal-weight individuals with elevated inflammatory markers, autoimmune patients who cannot afford weight loss This protocol uses the compounded tirzepatide dosage calculator approach since standard vials are not designed for sub-2.5 mg dosing
for example, highest-risk members in tier 1 could be covered with a $0 copay, while slightly lower-risk members in tier 3 could have some coverage but a greater copay
